arrow
D

Daniel J. Anderson

eikon therapeutics inc.
H指数:25
被引数:7,020

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven Cancers

单分子追踪赋能的快速优化:发现一种强效RUVBL1/2抑制剂以评估MYC驱动型癌症的靶向治疗

2026-04-220
OA
2024 VCP International Conference: Exploring multi-disciplinary approaches from basic science of valosin containing protein, an AAA plus ATPase protein, to the therapeutic advancement for VCP-associated multisystem proteinopathy
2025-03-010
OA
WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis
2024-07-182
OAAI
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor

通过选择性第二代小分子抑制剂靶向急性髓系白血病对VCP介导的DNA修复的依赖性

2021-03-3135
OA
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
2017-11-0195
OAAI
Utilization of K48 poly-ubiquitin modulation as a biomarker of target engagement for a protein homeostasis inhibitor in the clinic: Preclinical validation with CB-5083 a first-in-class inhibitor of the AAA ATPase p97
2016-07-150
PRE
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)
2015-12-04155
OAAI
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
2015-01-15431
OAAI
CB-5083 is a novel first in class p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models
2014-10-010
PRE
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death
2013-07-28306
PRE